Bantam's eIF4E inhibitors disrupt oncogene translation and cancer metabolism
Bantam Pharmaceutical LLC is developing small molecule eukaryotic translation initiation factor 4E inhibitors that selectively inhibit translation of several tumor-promoting genes and disrupt cancer cell metabolism. It hopes to show the mechanism of its lead compound will lead to a therapeutic more potent or safer than competing compounds in the same pathway.
mRNA translation begins with binding of a ribosome to the 5' end of an mRNA. This is facilitated by eukaryotic initiation factors including the eukaryotic translation initiation factor 4F (eIF4F) complex, which comprises three subunits: eIF4E